Gilead Sciences is expected to report a significant decline in Q2 2026 earnings per share (EPS) to around -$7.26, a sharp drop from the previous year, while revenue is forecasted to grow 4% year-over-year to approximately $7.37 billion. The revenue growth is mainly attributed to strength in its HIV drug franchise. Analysts have recently lowered EPS estimates for both Q2 and the full year 2026, reflecting concerns about profitability despite the revenue increase. Investors will closely watch the upcoming earnings report for insights into the company's financial health and future outlook.
The 2026 National ORBIE Awards recognized outstanding leadership among chief information officers (CIOs) and chief information security officers (CISOs) across 11 categories, celebrating executives from major global and enterprise organizations. Winn...
Royalty Pharma reported a 6% increase in Portfolio Receipts to $773 million in Q2 2026, driven by a 14% rise in Royalty Receipts from key drugs like Tremfya and Evrysdi. The company acquired new royalty interests, including AstraZeneca’s cliramitug, ...
Compugen Ltd. reported progress in its MAIA-ovarian trial for platinum-sensitive ovarian cancer, expecting median progression-free survival data by Q1 2027, a potential milestone for its COM701 antibody. The company also highlighted advancements in p...
